{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T22:24:52Z","timestamp":1789770292789,"version":"4.0.1"},"reference-count":19,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2009,9,22]],"date-time":"2009-09-22T00:00:00Z","timestamp":1253577600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2010,1]]},"abstract":"<jats:p> <jats:bold>WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT <\/jats:bold> <\/jats:p><jats:p>\u2022\u2003Maraviroc is a CCR5 receptor antagonist, while raltegravir is a HIV\u20101 integrase inhibitor.<\/jats:p><jats:p>\u2022\u2003Based on the known metabolic pathways (CYP3A4 for maraviroc and UGT1A1 for raltegravir), interaction between the two drugs is unlikely. However, unexpected interactions have been reported for other antiretroviral drugs.<\/jats:p><jats:p>\u2022\u2003As both these drugs are likely to be used in combination, this study evaluated the pharmacokinetic interaction between them.<\/jats:p><jats:p> <jats:bold>WHAT THIS STUDY ADDS<\/jats:bold> <\/jats:p><jats:p>\u2022\u2003Relative to individual monotherapy, co\u2010administration resulted in a 20% and 33% decrease in mean <jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub>, and 14% and 37% decrease in mean AUC of maraviroc and raltegravir, respectively.<\/jats:p><jats:p>\u2022\u2003Co\u2010administration was generally safe and well tolerated in healthy subjects.<\/jats:p><jats:p>\u2022\u2003These changes are not likely to be clinically relevant, thus no dose adjustment is necessary.<\/jats:p><jats:p><jats:bold>AIMS<\/jats:bold> To assess the two\u2010way pharmacokinetic interaction between maraviroc and raltegravir.<\/jats:p><jats:p><jats:bold>METHODS<\/jats:bold> In this open\u2010label, multiple\u2010dose, fixed\u2010sequence study, 18 healthy, human immunodeficiency virus (HIV)\u2010seronegative subjects received the following: days 1\u20133 raltegravir 400\u2003mg q12h, days 4\u20135 washout, days 6\u201311 maraviroc 300\u2003mg q12h, and days 12\u201314 raltegravir 400\u2003mg q12h + maraviroc 300\u2003mg q12h. Serial 12\u2010h blood samples were collected on days 3 (raltegravir), 11 (maraviroc) and 14 (raltegravir + maraviroc). Plasma samples were assayed by validated liquid chromatography tandem mass spectrometry assays. Test\/reference ratios and 95% confidence intervals (CIs) were determined for pharmacokinetic parameters.<\/jats:p><jats:p><jats:bold>RESULTS<\/jats:bold> For maraviroc, the test\/reference % ratio (95% CI) for AUC<jats:sub>\u03c4<\/jats:sub> was 85.8 (78.7, 93.5), for <jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub> was 79.5 (64.8, 97.5) and for <jats:italic>C<\/jats:italic><jats:sub>min<\/jats:sub> was 90.3 (84.2, 96.9). For raltegravir, the test\/reference % ratio (95% CI) for AUC<jats:sub>\u03c4<\/jats:sub> was 63.3 (41.0, 97.6), for <jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub> was 66.8 (37.1, 120.0) and for <jats:italic>C<\/jats:italic><jats:sub>min<\/jats:sub> was 72.4 (55.1, 95.2). In all subjects, maraviroc average concentrations (AUC<jats:sub>\u03c4<\/jats:sub> divided by 12) were &gt;100\u2003ng\u2003ml<jats:sup>\u22121<\/jats:sup>, the threshold value below which there is an increased risk of virological failure. Based on clinical experience for raltegravir, mean <jats:italic>C<\/jats:italic><jats:sub>min<\/jats:sub> decreases &gt;60% are considered to be clinically relevant for short\u2010term activity; however, in the present study mean changes were only 28% and thus not considered to be of clinical relevance.<\/jats:p><jats:p><jats:bold>CONCLUSIONS<\/jats:bold> Co\u2010administration of maraviroc and raltegravir decreased systemic exposure of both drugs; however, these are not likely to be clinically relevant. Safety and efficacy studies may help in understanding the role of this combination in the treatment of HIV infection.<\/jats:p>","DOI":"10.1111\/j.1365-2125.2009.03546.x","type":"journal-article","created":{"date-parts":[[2009,9,22]],"date-time":"2009-09-22T14:24:12Z","timestamp":1253629452000},"page":"51-57","source":"Crossref","is-referenced-by-count":22,"title":["Assessment of the pharmacokinetics of co\u2010administered maraviroc and raltegravir"],"prefix":"10.1111","volume":"69","author":[{"given":"Emma","family":"Andrews","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Glue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanzhi","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penelope","family":"Crownover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall","family":"Tressler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharat","family":"Damle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,12,23]]},"reference":[{"key":"e_1_2_7_2_2","unstructured":"World Heath Organization.2007 AIDS Epidemic Update. Available athttp:\/\/data.unaids.org\/pub\/EPISlides\/2007\/2007_epiupdate_en.pdf(last accessed 2 October 2009)."},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/595701"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e3181846e2e"},{"key":"e_1_2_7_5_2","volume-title":"Marviroc (Selzentry\u00ae). United States Prescribing Information","year":"2008"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1086\/589289"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2008.03137.x"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2008.03133.x"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2008.03134.x"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2008.03130.x"},{"key":"e_1_2_7_11_2","volume-title":"Raltegravir (Isentress\u00ae). United States Prescribing Information","year":"2007"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2008.10.012"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100281"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.107.016196"},{"key":"e_1_2_7_15_2","unstructured":"Merck.ISENTRESS\u2122 (raltegravir) 400\u2003mg For Treatment of HIV(NDA 22\u2010145) 2007. Briefing Document. Presented as part of the FDA Antiviral Drugs Advisory Committee meeting held September 5 2007. Available athttp:\/\/www.fda.gov\/ohrms\/dockets\/ac\/07\/briefing\/2007\u20104314b1\u201001\u2010Merck.pdf(last accessed 6 March 2009)."},{"key":"e_1_2_7_16_2","doi-asserted-by":"crossref","unstructured":"NozzaS ViscoF SoriaA GalliL SalpietroS GianottiN CariniE BigoloniA FusettiG TambussiG LazzarinA CastagnaA.Excellent short\u2010term CD4 recovery with a PI\u2010 and NRTI\u2010sparing regimen in triple\u2010class failure HIV\u2010infected patients: raltegravir maraviroc etravirine. 9th International Congress on Drug Therapy in HIV Infection. Glasgow UK 9\u201313 November 2008. Abstract P045.","DOI":"10.1186\/1758-2652-11-S1-P45"},{"key":"e_1_2_7_17_2","first-page":"15","article-title":"Determination of the HIV integrase inhibitor, MK\u20100518 (raltegravir), in human plasma using 96\u2010well liquid\u2013liquid extraction and HPLC\u2010MS\/MS","volume":"857","author":"Merschman SA","year":"2007","journal-title":"J Chromatogr"},{"key":"e_1_2_7_18_2","unstructured":"McFadyenL JacqminP WadeJR WeatherleyB ChanPLS.Maraviroc (MVC) exposure\u2013efficacy relationship HIV\u20101\u2010infected patients. 11th European AIDS Conference \/ EACS. Madrid Spain 24\u201327 October 2007. Poster P4.1\/06."},{"key":"e_1_2_7_19_2","unstructured":"McFadyenL JacqminP WadeJR WeatherleyB.Maraviroc exposure\u2010efficacy (<50 copies\/mL) analysis in HIV\u20101\u2010infected treatment\u2010na\u00efve subjects \u2013 ITT Population (MERIT Study). XVII International AIDS Conference Mexico City Mexico 3\u20138 August 2008. Poster TUPE0053."},{"key":"e_1_2_7_20_2","unstructured":"WenningL NguyenBY SunX HwangE ChenY TepplerH HarveyC RhodesR RyanD AzrolanN StoneJ.Pharmacokinetic\/pharmacodynamic (PK\/PD) analyses of raltegravir in phase II and III studies in treatment\u2010experienced HIV patients. 9th International Workshop on Clinical Pharmacology of HIV Therapy. New Orleans USA 7\u20139 April 2008."}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2009.03546.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2009.03546.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T01:55:29Z","timestamp":1697421329000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2009.03546.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12,23]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["10.1111\/j.1365-2125.2009.03546.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2009.03546.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12,23]]}}}